MetalloBio has secured more than £1.5m to bring new antimicrobial class to the pharmaceutical market
A Sheffield company that has secured more than £1.5m seed funding to allow it to carry out ground-breaking research into new antibiotics that could save millions of lives has established a new base in Sheffield’s UKSE Innovation Centre, which will accommodate its growing management and technical team.
Widely recognised as one of the biggest threats to global health, antimicrobial resistance (AMR) is responsible for 1.2 million deaths per year globally – MetalloBio’s move will allow the company to continue to deliver on its research into the development of a completely new class of antibiotics to tackle this growing problem.
With the global antibiotics market projected to reach $55.8 billion/annum by 2023, and with reports that in the United States alone 1 patient dies every 15 minutes from an AMR infection, MetalloBio plans to continue its growth and research locally and so the company has chosen the UKSE Innovation Centre for its base given its close proximity to the University of Sheffield’s labs, where vital R&D work is carried out.
Commenting on the move into the impressive, centrally located Innovation Centre, MetalloBio’s COO Richard Senior, said: “The innovation centre represented the perfect HQ for us, it is close to the labs we use and Sheffield-based collaborators we are working with, it’s walkable for those within the team who live in Sheffield and very accessible for those who live slightly further away.
“MetalloBio are currently fundraising, which if successful would mean that the company headcount will grow as we continue to innovate the first new antimicrobial compounds to emerge for nearly 40 years.”
Welcoming the new tenants Steve Lyon, Area Manager at UKSE, said: “We’re delighted to welcome MetaloBio to the UKSE Innovation Centre, which is ideally situated in the City Centre, close to both Universities.”